发明名称 Melanocortin Receptor Ligands
摘要 The present invention is directed to compounds according to formula,;(R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1,;and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
申请公布号 US2016368962(A1) 申请公布日期 2016.12.22
申请号 US201615257970 申请日期 2016.09.07
申请人 Ipsen Pharma S.A.S. 发明人 DONG Zheng Xin;MOREAU Jacques-Pierre
分类号 C07K14/665;C07K7/06 主分类号 C07K14/665
代理机构 代理人
主权项 1. A compound according to formula (I): (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1 wherein: A1 is Acc, HN—(CH2)m—C(O), L- or D-amino acid or deleted; A2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp or Glu; A3 is Gly, Ala, β-Ala, Gaba, Aib, D-amino acid or deleted; A4 is His, 2-Pal, 3-Pal, 4-Pal, Taz, 2-Thi, 3-Thi or (X1,X2,X3,X4,X5)Phe; A5 is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal, D-(X1,X2,X3,X4,X5)Phe, L-Phe or D-(Et)Tyr; A6 is Arg, hArg, Dab, Dap, Lys, Orn or HN—CH((CH2)n—N(R4R5))—C(O); A7 is Trp, 1-Nal, 2-Nal, Bal, Bip, D-Trp, D-1-Nal, D-2-Nal, D-Bal or D-Bip; A8 is Gly, D-Ala, Acc, Ala, β-Ala, Gaba, Apn, Ahx, Aha, HN—(CH2)s—C(O) or deleted; A9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Dab, Dap, Orn or Lys; A10 is Acc, HN—(CH2)t—C(O), L- or D-amino acid or deleted; R1 is —OH or —NH2; R2 and R3 is, independently for each occurrence, H, (C1-C30)alkyl, (C1-C30)heteroalkyl, (C1-C30)acyl, (C2-C30)alkenyl, (C2-C30)alkynyl, aryl(C1-C30)alkyl, aryl(C1-C30)acyl, substituted (C1-C30)alkyl, substituted (C1-C30)heteroalkyl, substituted (C1-C30)acyl, substituted (C2-C30)alkenyl, substituted (C2-C30)alkynyl, substituted aryl(C1-C30)alkyl or substituted aryl(C1-C30)acyl; R4 and R5 is, independently for each occurrence, H, (C1-C40)alkyl, (C1-C40)heteroalkyl, (C1-C40)acyl, (C2-C40)alkenyl, (C2-C40)alkynyl, aryl(C1-C40)alkyl, aryl(C1-C40)acyl, substituted (C1-C40)alkyl, substituted (C1-C4)heteroalkyl, substituted (C1-C40) acyl, substituted (C2-C40)alkenyl, substituted (C2-C40)alkynyl, substituted aryl(C1-C40)alkyl, substituted aryl(C1-C40)acyl, (C1-C40)alkylsulfonyl or —C(NH)—NH2; m is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7; n is, independently for each occurrence, 1, 2, 3, 4 or 5; s is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7; t is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7; and X1, X2, X3, X4, and X5 each is, independently for each occurrence, H, F, Cl, Br, I, (C1-10)alkyl, substituted (C1-10)alkyl, (C2-10)alkenyl, substituted (C2-10)alkenyl, (C2-10)alkynyl, substituted (C2-10)alkynyl, aryl, substituted aryl, OH, NH2, NO2, or CN; provided that (I). when R4 is (C1-C40)acyl, aryl(C1-C40)acyl, substituted (C1-C40)acyl, substituted aryl(C1-C40)acyl, (C1-C40)alkylsulfonyl or —C(NH)—NH2, then R5 is H, (C1-C40)alkyl, (C1-C40)heteroalkyl, (C2-C40)alkenyl, (C2-C40)alkynyl, aryl(C1-C40)alkyl, substituted (C1-C40)alkyl, substituted (C1-C40)heteroalkyl, substituted (C2-C40)alkenyl, substituted (C2-C40)alkynyl or substituted aryl(C1-C40)alkyl; (II). when R2 is (C1-C30)acyl, aryl(C1-C30)acyl, substituted (C1-C30)acyl or substituted aryl(C1-C30)acyl, then R3 is H, (C1-C30)alkyl, (C1-C30)heteroalkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, aryl(C1-C30)alkyl, substituted (C1-C30)alkyl, substituted (C1-C30)heteroalkyl, substituted (C2-C30)alkenyl, substituted (C2-C30)alkynyl or substituted aryl(C1-C30)alkyl; (III). either A3 or A8 or both must be present in said compound; (IV). when A2 is Cys, D-Cys, hCys, D-hCys, Pen or D-Pen, then A9 is Cys, D-Cys, hCys, D-hCys, Pen or D-Pen; (V). when A2 is Asp or Glu, then A9 is Dab, Dap, Orn or Lys; (VI). when A8 is Ala or Gly, then A1 is not Nle; and (VII). when A1 is deleted, then R2 and R3 cannot both be H;or a pharmaceutically acceptable salt thereof.
地址 Boulogne-Billancourt FR